- Home
- MYN vs CLLS Comparison
MYN vs CLLS Comparison
Compare MYN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYN | CLLS |
|---|---|---|
| Founded | 1992 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.4M | 384.3M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MYN | CLLS |
|---|---|---|
| Price | $9.93 | $3.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 178.3K | 43.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.13 | $1.10 |
| 52 Week High | $10.26 | $5.48 |
Technical Indicators
Market Signals| Indicator | MYN | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.39 | 40.31 |
| Support Level | $9.90 | $3.41 |
| Resistance Level | $10.21 | $3.77 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 30.00 | 11.98 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.